{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-018455","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.172573+00:00","generated_at":"2026-06-24T21:25:30.570544+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Anebulo's ANEB-001 meets primary endpoint in Phase 2 ACI trial (p<0.0001)","bullets":["Primary endpoint VAS 'Feeling High' met (p<0.0001) for both 50mg and 100mg ANEB-001 vs placebo.","Only 10% (50mg) and 30% (100mg) reported feeling high vs 75% placebo (p<0.001).","ANEB-001 well tolerated; all AEs mild/transient except one moderate nausea/vomiting in 50mg group.","Part B of study planned for Q3 2022; U.S. IND submission expected by end of 2022.","Conference call at 8:30am ET today to discuss topline results."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-018455","json":"https://secwatch.observer/filing/0001493152-22-018455.json","markdown":"https://secwatch.observer/filing/0001493152-22-018455.md","text":"https://secwatch.observer/filing/0001493152-22-018455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/0001493152-22-018455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222018455/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:25:30.570544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}